Day One Biopharmaceuticals Inc stock PB Ratio (=5.03) is close to 2-year high of 5.03.
The historical rank and industry rank for Day One Biopharmaceuticals's PB Ratio or its related term are showing as below:
DAWN'
s PB Ratio Range Over the Past 10 Years
Min: 1.32 Med: 2.32 Max: 5.03
Current: 5.03
During the past 7 years, Day One Biopharmaceuticals's highest PB Ratio was 5.03. The lowest was 1.32. And the median was 2.32.
DAWN's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.97
vs DAWN: 5.03
During the past 12 months, Day One Biopharmaceuticals's average Book Value Per Share Growth Rate was -13.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -1.80% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Day One Biopharmaceuticals was 3.10% per year. The lowest was -1.80% per year. And the median was 0.65% per year.
Back to Basics: PB Ratio
Day One Biopharmaceuticals (NAS:DAWN) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Day One Biopharmaceuticals PB Ratio Related Terms
Day One Biopharmaceuticals PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Day One Biopharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Day One Biopharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Day One Biopharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Day One Biopharmaceuticals (DAWN) has a PB Ratio of 5.03 as of Jul. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Day One Biopharmaceuticals and its competitors. This is 117% above median its historical median of 2.32. Over the past decade, Day One Biopharmaceuticals' PB Ratio has ranged from 1.32 to 5.03.
Is Day One Biopharmaceuticals' PB Ratio too high?
Day One Biopharmaceuticals' current PB Ratio of 5.03 is 117% above median its 10-year median of 2.32. Over the past 10 years, this metric has ranged from a low of 1.32 to a high of 5.03. The Biotechnology industry median PB Ratio is 2.97. Day One Biopharmaceuticals' value of 5.03 is 69.4% above this industry median. Overall, Day One Biopharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Day One Biopharmaceuticals' PB Ratio compare to TYRA and DFTX?
Day One Biopharmaceuticals' PB Ratio of 5.03 can be compared against companies in the Biotechnology industry. The industry median PB Ratio is 2.97. Day One Biopharmaceuticals' value of 5.03 is 69.4% above this benchmark. Historically, Day One Biopharmaceuticals' own PB Ratio has ranged from 1.32 to 5.03 over the past decade. While the company's 10-year median is 2.32 vs. the industry median of 2.97, Day One Biopharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.97, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Day One Biopharmaceuticals's current PB Ratio of 5.03 is 69.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Day One Biopharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Day One Biopharmaceuticals's current PB Ratio is 5.03, which is 117% above median its own 10-year median of 2.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Day One Biopharmaceuticals stock overvalued right now?
Day One Biopharmaceuticals (DAWN) has a current PB Ratio of 5.03. The current PB Ratio is 5.03, which is 117% above median its 10-year median of 2.32 and 69.4% above the Biotechnology industry median of 2.97. Day One Biopharmaceuticals' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Day One Biopharmaceuticals (DAWN), the current PB Ratio is 5.03 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
12GF Score
Get the complete analysis for DAWN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DAWN has been successfully added to your 
